Days after its lead clinical-stage asset suffered a setback, Agios Pharmaceuticals has rebounded by buying a blood disorder drug that flunked a phase 2 study.
- Home |
- Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
Agios signs $165M deal for blood disorder drug from Korea’s Oscotec that flunked phase 2 study
- June 1, 2026
Recent Posts
- LNG market tightens into winter as Europe pulls US cargoes, China reopens contract talks
- EIA: US crude oil inventories down 3.2 million bbl
- Chevron restructures Bakken midstream agreements, transfers Hess Midstream stake
- Cenovus to build oil sands business via Athabasca acquisition
- Centalion acquires Haynesville gas assets from Silver Hill
